Gilead’s HIV sales grew 18% year over year in the third quarter of 2026. Management attributed growth to Biktarvy, Descovy and Yeztugo, and said Biktarvy reached an all-time high in the U.S. Management expects HIV revenue to grow approximately 12% in 2026, supported by these products.
Key facts
Gilead expects HIV revenues to grow approximately 12% in 2026, supported by Biktarvy, Descovy and Yeztugo. source
Gilead's third-quarter 2026 HIV sales increased 18% year over year. source